Union Budget 2026–27 Strengthens Biopharma, Medical Tourism and Wellness
Sujay Shetty, Partner and Leader – Health Industries, PwC India, said the Union Budget 2026–27 reinforces India’s commitment to the biopharma sector.
He welcomed initiatives aimed at strengthening biomanufacturing, expanding skills development through additional NIPERs, and accelerating approval timelines, noting that these measures improve ease of doing business and regulatory efficiency.
Shetty also highlighted the focus on medical tourism, positioning India as a global destination for high-quality, affordable healthcare, and on Ayurveda and wellness, which will enhance global competitiveness, create jobs, and open new opportunities for innovation and exports.
